| Name | Title | Contact Details |
|---|
Galileo is a modern medical practice that provides full spectrum medical care, from urgent to chronic, across digital and in-person settings. They bring the best doctors to patients: at home, in the community, and on their mobile device.
INTEGRIS Health is Oklahoma`s largest health system with hospitals, rehabilitation centers, physician clinics, mental health facilities, independent living centers and home health agencies located throughout the state. INTEGRIS Health is a not-for-profit corporation. It was organized under the laws of the state of Oklahoma for charitable, scientific and educational purposes and specifically to engage in the delivery of health-care services and related activities. INTEGRIS Health is governed by an 11 to 15-member board of directors made up of business and community leaders from across the state. It`s managed by President and Chief Executive Officer Bruce Lawrence, with the assistance of senior staff in the areas of physician services, facility operations, strategic services and finance. INTEGRIS Health is a not-for-profit corporation formed in 1983 to serve as the parent corporation for, and to provide management and administrative support to, INTEGRIS Baptist Medical Center Inc., another Oklahoma not-for-profit corporation that operates a tertiary care hospital in northwest Oklahoma City. In 1994, INTEGRIS Health merged with Baptist Healthcare of Oklahoma, an event that brought to the organization a network of outstanding rural hospitals across the state. In 1995, INTEGRIS Health merged with Southwest Medical Center, an acute-care hospital in southwest Oklahoma City. Each of these organizations brings a rich history of serving Oklahomans. INTEGRIS Health, along with these and a number of other affiliated entities, form the INTEGRIS Health system.
Whitecourts Interagency Food Bank is a Whitecourt, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.
Clinical Research Group is a Villanova, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.